In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against organisms other than staphylococci

Junius Clark; Joan C Fung-Tomc; Beatrice Minassian; Yuan-Hwang Tsai; Hyekyung Yang; Elizabeth Huczko; Benjamin Kolek; Susan Chaniewski; Cheryl Ferraro; Rebecca Drain; Elizabeth Gradelski; Daniel P Bonner

doi:10.1128/AAC.46.4.1108-1111.2002

In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against organisms other than staphylococci

Antimicrob Agents Chemother. 2002 Apr;46(4):1108-11. doi: 10.1128/AAC.46.4.1108-1111.2002.

Authors

Junius Clark¹, Joan C Fung-Tomc, Beatrice Minassian, Yuan-Hwang Tsai, Hyekyung Yang, Elizabeth Huczko, Benjamin Kolek, Susan Chaniewski, Cheryl Ferraro, Rebecca Drain, Elizabeth Gradelski, Daniel P Bonner

Affiliation

¹ Department of Microbiology, Bristol-Myers Squibb Co., Wallingford, Connecticut 06492, USA.

Abstract

BMS-247243, a novel cephalosporin inhibitory for methicillin-resistant staphylococci, primarily has activity against gram-positive bacteria. The activities of BMS-247243, cefotaxime, and ceftriaxone against streptococci and Streptococcus pneumoniae were similar. BMS-247243 inhibits Enterococcus faecalis but not Enterococcus faecium. BMS-247243 also inhibits many inherently vancomycin-resistant species (Leuconstoc, Lactobacillus, Pediococcus) and anaerobic gram-positive bacteria.

MeSH terms

Animals
Bacteria / drug effects
Cephalosporins / pharmacology*
Drug Resistance, Microbial
Female
Gram-Positive Bacteria / drug effects*
Gram-Positive Bacterial Infections / microbiology
Humans
Immunosuppression Therapy
Mice
Mice, Inbred ICR
Microbial Sensitivity Tests
Morpholines / pharmacology*
Penicillin Resistance
Pneumococcal Infections / drug therapy
Pneumococcal Infections / microbiology
Pyridines / pharmacology*
Time Factors

Substances

Cephalosporins
Morpholines
Pyridines
BMS-247243